Valiant Laboratories

Valiant Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 1,444.26 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 5,112.68 % — a change of -71.75% (lower).

FCF Conversion

1,444.26 %

YoY

-71.75%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Valiant Laboratories is 2026 1,444.26 % . FCF Conversion Rate (FCF/EBITDA) of Valiant Laboratories was 2025 5,112.68 % . It decreases by -71.75% lower compared to the previous year.

The Valiant Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
24.32 INR
Jan 1, 2022
-16.82 INR
Jan 1, 2023
63.35 INR
Jan 1, 2024
-13,762.48 INR
Jan 1, 2025
5,112.68 INR
Jan 1, 2026
1,444.26 INR
The Valiant Laboratories FCF Conversion history
YEARFCF ConversionYoY
1,444.26 %-71.75%
5,112.68 %-137.15%
-13,762.48 %-21,824.79%
63.35 %-476.62%
-16.82 %-169.17%
24.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Valiant Laboratories is 1,444.26 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Valiant Laboratories changed from 5,112.68 % to 1,444.26 %, representing a -71.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valiant Laboratories

All Key Metrics — Valiant Laboratories